P53 Gene mutation and expression of MDM2, P53, P16 protein and their relationship in human glioma

Abstract

To investigate the effect of P53 protein accumulation and p53 gene mutation in the pathogenesis of glioma and to study the role of MDM2, P53 and P16 protein in glioma formation and progression and their relationship with each other, LSAB immunohistochemical staining method and non-isotopic PCR-SSCP techniques were used to detect the expression of MDM2, P53 and P16 protein and p53 gene mutation in 48 cases of gliomas. The results showed that the positive expression rate of MDM2, P53 and the negative rate of P16 was 22.9%, 41.7% and 60.4%, respectively. The latter two in high grade (grade III, IV) gliomas had a significantly higher rate than in the low grade (grade II) gliomas. Moreover, the co-expression of MDM2 and P53 protein was confirmed in only 1 of 48 cases. No significant difference was found in the rate of the expression of MDM2 between high grade and low grade gliomas (P>0.1). PCR-SSCP results showed that mutation of 5–8 exons of p53 gene was detected in 17 out of 48 cases (35.42%). Mutation was detected in 16 of 20 cases of positive p53 expression, and another one was detected in 28 cases of negative expression cases. The correlation between p53 mutation and p53 mutation and p53 immunopositivity was observed in 89.6% of the cases. P53 gene mutation and the level of MDM2, P53 and P16 protein were not related to age, gender of the patients, tumor location and size. It is concluded that the mutation of p53 and deletion of p16 might play important roles in the tumorigenesis of gliomas and it was significantly associated with the grade of tumor differentiation. P53 protein accumulation can indirectly reflect p53 mutation. MDM2 amplification and overexpression might be an early event in the growth of human gliomas.

Keywords

gliomas / gene mutation / gene product

References

[1] CuiW, FanL J, WangX, et al. . Expression of HER-2/neu oncoprotein and mRNA In human thyroid carcinomas. Chin Tumor (Chinese), 2000, 9(11): 526-526

[2] CuiW, KongL L, LiH F, et al. . Detection of point mutation of p53 gene by non-isotopic PCR-SSCP in thyroid carcinomas. J Jining Med College (Chinese), 2001, 24(1): 4-4

[3] KuchelmeisterK, ElborgB, GullottaF, et al. . Immunohistochemical detection of p53 protein in tumors of the central nervous system. Pathologica, 1995, 87: 498-498

[4] KrausA, NeffF, BehnM, et al. . Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells. Int J Cancer, 1999, 80: 930-930

[5] KarC, ChattopadhyayP, RalteA M, et al. . Loss of heterozygosity of a locus in the chromosomal region 17p13, 3 is associated with increased cell proliferation in astrocytic tumors. Cancer Genet Cytogenet, 2003, 144: 156-156

[6] HayashiK, YandellD W. How sensitive is PCR-SSCP?. Hum Mutat, 1993, 2: 338-338

[7] KatoH, KatoS, KumabeT, et al. . Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res, 2000, 6: 3937-3937

[8] RanuncoloS M, VarelaM, MorandiA, et al. . Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas. J Neurooncol, 2004, 68: 113-113

[9] IwakumaT, LozanoG. MDM2, an introduction. Mol Cancer Res, 2003, 1: 993-993

[10] HungK S, HongCY, LeeJ, et al. . Expression of p16 (INK4A) induces dominant suppression of glioblastoma growth in situ through necrosis and cell cycle arrest. Biochem Biophys Res Commun, 2000, 269: 718-718

[11] TortosaA, VinolasN, VillaS, et al. . Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer, 2003, 97(4): 1063-1063